Submission to the Consultation on the Medical Services Advisory Committee (MSAC) Revised Draft Guidelines

Submitted on 2020-10-12


The Medicines Service Advisory Committee (MSAC) appraises medical services, health technologies and/or programs proposed for public funding, and provides advice to Government about the level and quality of evidence relating to the comparative safety, clinical effectiveness, cost-effectiveness, and total cost of providing such services.


MSAC has released new draft guidelines for consultation. The Guidelines provide advice to applicants and assessment groups on the health technology assessment (HTA) methods used by Medical Services Advisory Committee (MSAC) to assess requests for public funding that fall within the remit of MSAC, e.g. Medicare Benefits Schedule (MBS) services, national screening programmes, blood products for the National Product List (NPL), and technologies which may be funded via other mechanisms.


Our submission to the consultation on the Medical Services Advisory Committee (MSAC) Revised Draft Guidelines represents a joint response prepared by a group of Health Technology Assessment consultancies: HTAccess Consulting, Shoten Consulting, Lucid Health Consulting and THEMA Consulting. Each organisation has extensive experience in the preparation of Assessment Reports for consideration by MSAC and will be users of the updated MSAC Guidelines. None of our organisations were sought out for comment in the preparation of the Draft Guidelines.


The comments and feedback on the Draft Guidelines provided herein represent a consensus position from all parties. It does not necessarily reflect the views of any of our clients. It is hoped that the feedback provided is valuable to the MSAC Guidelines Review team in shaping the final version of the updated MSAC Guidelines.

See Full Submission in attached PDF Document.

MSAC Guidelines Consultation Response_HTAccess, Shoten, Lucid Health and THEMA


For more information about MSAC’s or to discuss how Lucid Health Consulting can assist your organisation, please contact George Papadopoulos, Director of Lucid Health Consulting on email: or phone: + 61 435 934 394.


About the Author:

George Papadopoulos, Partner and Director at Lucid Health Consulting. George is a Health Economist, Pricing and Reimbursement and Strategic Market Access Expert with over 25 years in the healthcare industry in both Australia and USA.  An experienced key speaker and commentator, his current leadership roles include chairman of ARCS Australia and Adjunct Senior Lecturer at UNSW, Pharmaceutical Medicine.

Connect with George on LinkedIn.